The Prognostic Significance of Beta2 Microglobulin in Patients with Hemophagocytic Lymphohistiocytosis

Disease Markers

Volumn 2016, Issue , 2016, Pages

  Jiang, Tiantong ^a   Ding, Xiurong ^b   Lu, Weixing ^a  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE THIRD AFFILIATED HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA 2 MICROGLOBULIN; FERRITIN; FIBRINOGEN; HEMOGLOBIN; LACTATE DEHYDROGENASE; TRIACYLGLYCEROL;

ADULT; ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISEASE SEVERITY; EPSTEIN BARR VIRUS; ERYTHROPHAGOCYTOSIS; FEMALE; HEMOPHAGOCYTIC SYNDROME; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; HYPOFIBRINOGENEMIA; IMMUNE SYSTEM; LARGE CELL LYMPHOMA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PARVOVIRIDAE; PHOTOMETRY; PNEUMONIA; PROGNOSIS; SJOEGREN SYNDROME; SUBCUTANEOUS T CELL LYMPHOMA; T CELL LYMPHOMA; THROMBOCYTOPENIA; TUBERCULOSIS; UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE; BLOOD; LYMPHOMA; METABOLISM; MIDDLE AGED; MORTALITY; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL ANALYSIS; UPREGULATION; YOUNG ADULT;

ADULT; BETA 2-MICROGLOBULIN; FEMALE; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; LYMPHOMA; MALE; MIDDLE AGED; PROGNOSIS; ROC CURVE; SURVIVAL ANALYSIS; UP-REGULATION; YOUNG ADULT;

EID: 84971384457     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2016/1523959     Document Type: Article

References (27)

1. G. E. Janka, "Hemophagocytic syndromes, " Blood Reviews, vol. 21, no. 5, pp. 245-253, 2007.
2. F. G. N. Rosado and A. S. Kim, "Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis, " American Journal of Clinical Pathology, vol. 139, no. 6, pp. 713-727, 2013.
3. S. F. N. Bode, K. Lehmberg, A. Maul-Pavicic et al., "Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis, "Arthritis Research andTherapy, vol. 14, no. 3, p. 213, 2012.
4. E. Ishii, S. Ohga, S. Imashuku et al., "Nationwide survey of hemophagocytic lymphohistiocytosis in Japan, " International Journal of Hematology, vol. 86, no. 1, pp. 58-65, 2007.
5. M. Machaczka, J. Vaktnäs, M. Klimkowska, and H. Hägglund, "Malignancy-associated hemophagocytic lymphohistiocytosis in adults: a retrospective population-based analysis from a single center, " Leukemia and Lymphoma, vol. 52, no. 4, pp. 613-619, 2011.
6. J. Bladé, M. T. Cibeira, C. Fernández de Larrea, and L. Rosiñol, "Multiple myeloma, " Annals of Oncology, vol. 21, supplement 7, pp. 313-319, 2010.
7. M. Z. Penz, W. C. C. Fiebiger, J. B. Valencak et al., "Beta-2-microglobulin levels in patients with extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type: a retrospective analysis, " Anticancer Research, vol. 21, no. 4, pp. 3049-3052, 2001.
8. T. P. Vassilakopoulos, G. Nadali, M. K. Angelopoulouet al., "The prognostic significance of beta (2)-microglobulin in patients with Hodgkin's lymphoma, " Haematologica, vol. 87, no. 7, pp. 701-708, 2002.
9. S. Shinkai, P. H. M. Chaves, Y. Fujiwara et al., "2-microglobulin for risk stratification of total mortality in the elderly population: comparison with cystatin C and C-reactive protein, " Archives of Internal Medicine, vol. 168, no. 2, pp. 200-206, 2008.
10. S. Hibi, S. Ikushima, F. Fujiwara et al., "Serum and urine beta-2-microglobulin in hemophagocytic syndrome, " Cancer, vol. 75, no. 7, pp. 1700-1705, 1995.
11. J.-I. Henter, A. Horne, M. Aricó et al., "HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis, " Pediatric Blood and Cancer, vol. 48, no. 2, pp. 124-131, 2007.
12. S. H. Swerdlow, E. Campo, N. L. Harris et al., WHO Classification of Tumours ofHaematopoietic and Lymphoid Tissues, IARC, Lyon, France, 4th edition, 2008.
13. Y. W. Koh, H. J. Kang, C. Park et al., "Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic hodgkin lymphoma, " American Journal of Clinical Pathology, vol. 138, no. 6, pp. 846-854, 2012.
14. S. A. Parikh, P. Kapoor, L. Letendre, S. Kumar, and A. P. Wolanskyj, "Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis, " Mayo Clinic Proceedings, vol. 89, no. 4, pp. 484-492, 2014.
15. C. Yoo, D. H. Yoon, and C. Suh, "Serumbeta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor, " Blood Research, vol. 49, no. 3, pp. 148-153, 2014.
16. C. Shi, Y. Zhu, Y. Su, L. W. K. Chung, and T. Cheng, "2-Microglobulin: emerging as a promising cancer therapeutic target, " Drug Discovery Today, vol. 14, no. 1-2, pp. 25-30, 2009.
17. Z.-M. Li, Y.-J. Zhu, J. Sun et al., "Serum beta2-microglobin is a predictor of prognosis in patients with upper aerodigestive tract NK/T-cell lymphoma, " Annals of Hematology, vol. 91, no. 8, pp. 1265-1270, 2012.
18. E. Aulbert and O. Steffens, "Beta 2 microglobulin in serum-a 'tumor marker' inmalignant lymphomas" Medizinische Klinik, vol. 85, no. 1, pp. 13-17, 1990.
19. S. Alici, S. E. Bavbek, E. Kaytan, Y. Eralp, and H. Onat, "Prognostic factors in localized aggressive non-Hodgkin's lymphoma, " American Journal of Clinical Oncology, vol. 26, no. 1, pp. 1-5, 2003.
20. J. E. Romaguera, L. Fayad, M. A. Rodriguez et al., "High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine, " Journal of Clinical Oncology, vol. 23, no. 28, pp. 7013-7023, 2005.
21. A. López-Guillermo, L. Colomo, M. Jiménez et al., "Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin, " Journal of Clinical Oncology, vol. 23, no. 12, pp. 2797-2804, 2005.
22. G. M. Chronowski, R. B. Wilder, S. L. Tucker et al., "An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease, " Cancer, vol. 95, no. 12, pp. 2534-2538, 2002.
23. F. Swan Jr., W. S. Velasquez, S. Tucker et al., "A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels, " Journal of Clinical Oncology, vol. 7, no. 10, pp. 1518-1527, 1989.
24. P. Möller, B. Herrmann, G. Moldenhauer, and F. Momburg, "Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high-grade malignancy, " International Journal of Cancer, vol. 40, no. 1, pp. 32-39, 1987.
25. M. Mori, Y. Terui, M. Ikeda et al., "2-microglobulin identified as an apoptosis-inducing factor and its characterization, " Blood, vol. 94, no. 8, pp. 2744-2753, 1999.
26. M. Mori, Y. Terui, M. Tanaka et al., "Antitumor effect of beta2-microglobulin in leukemic cell-bearing mice via apoptosisinducing activity: activation of caspase-3 and nuclear factorkappaB, " Cancer Research, vol. 61, no. 11, pp. 4414-4417, 2001.
27. H. Trottestam, E. Berglöf, A. Horne et al., "Risk factors for early death in children with haemophagocytic lymphohistiocytosis, " Acta Paediatrica, vol. 101, no. 3, pp. 313-318, 2012.